Navigation Links
Bioheart, Inc. Announces Financial Results for Second Quarter 2008
Date:7/30/2008

follow this mark.

-- On July 2, 2008, the Company announced it was added to the Russell Microcap Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2008.

-- On July 1, 2008 the Company's Board of Directors appointed Howard J. Leonhardt, Bioheart's co-founder, Chairman of the Board and Chief Technology Officer, to serve as Chief Executive Officer.

Revenues for the quarter ended June 30, 2008 were $16,786 compared to $194,609 in the second quarter of 2007. During the quarter, the Company also recognized $15,000 of development revenue for services performed under a clinical registry agreement. The Company reported a net loss for the second quarter of 2008 of $3.9 million, or $(0.27) per share, compared to a net loss of $2.8 million, or $(0.21) per share, for the same quarter last year. The Company ended the quarter with cash and cash equivalents totaling $1.9 million.

The increase in the Company's net loss in the second quarter of 2008 as compared to the second quarter of 2007 is primarily attributable to increased stock-based compensation and interest expense related to $10 million of debt incurred by the Company in June 2007.

Research and development expenses for the second quarter of 2008 were $1.5 million compared to $1.8 million in the second quarter last year. The primary focus of the Company's research and development activities during the quarter related to the MARVEL Trial. The MARVEL Trial is the largest clinical trial of its kind to date, investigating the use of autologous myoblasts to treat patients suffering from congestive heart failure. These myoblasts, adult stem cells that are precursors to muscle, are derived from the patient's own body. When injected into scar tissue within the heart wall, myoblasts have shown they are capable of engrafting in the damaged tissue and differentiating into mature muscle cells capable of augmenting cardiac function
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. to Transfer to Nasdaq Capital Market
6. Bioheart, Inc., Added to Russell Microcap Index
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. Announces Results of Annual Meeting
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , October 30, 2014 Investor-Edge ... Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,549.23, down 0.33%, the Dow Jones Industrial Average ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada has ... detects CYP2C19 genetic mutations in less than 60 minutes ... CYP2C19 System is the first near-patient DNA test for ... to the system’s ease of use, Health Canada has ... such as doctors, nurses, pharmacists, and laboratory technicians, in ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Society, an,international association focused on endocrinological research and,practice, today ... ENDO 08, the annual conference of the Society, which ... over 14,000 members from 80,countries, many of whom attend ... research and clinical care., The purpose of today,s ...
... industry, academia, government and health providers draws dozens of ... ... June 16 The unique connectivity, talent and,collaboration that has ... in recent years will be on show at BIO 2008 ...
... today announced,the appointment of Jim Meade, Ph.D., ... addition to contributing to the strategic direction ... for managing the development of,Lentigen,s partnerships, stakeholder ... and other key aspects of,corporate development., ...
Cached Biology Technology:'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 3Lentigen Appoints Jim Meade as Vice President of Corporate Development 2
(Date:10/30/2014)... October 30, 2014 – Bacteria in the gastrointestinal ... for digestion. Yet, these same bacteria can induce ... they penetrate the gut and enter the bloodstream. ... to protect the body, chronic or systemic inflammation ... research has established the involvement of inflammatory processes ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
Breaking Biology News(10 mins):Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... stage is set for the local fauna! ,Computer scientists ... birdsong archives of Berlin,s Humboldt University, have developed a kind ... with entertainment, but a lot to do with the protection ... reliably recognise the characteristic birdsong of different species of birds, ...
... drop to dangerously low levels in diseases such as ... critical cells, doctors filter platelets from donated blood, but ... infections and cause other side effects in patients who ... scientists have been trying to generate platelets from embryonic ...
... on opposite sides of a canyon have evolved to cope ... or cell membranes. Scientists have found that bacteria change these ... looking at the appearance of the bacteria as well as ... August issue of Microbiology , will start a new ...
Cached Biology News:Birdsong not just for the birds 2Bacteria reveal secret of adaptation at Evolution Canyon 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... Mouse anti-Yersinia pestis F1 antigen, ... Applications: ELISA: Use at ... at an assay dependent dilution. WB: ... Predicted molecular weight: 18 kDa. Not ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
Biology Products: